Clinical Trial Update: Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating neoadjuvant donafenib combined with a PD-1 inhibitor for locally advanced thyroid cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Anti-PD-1 antibody
• Donafenib (donafenib)

Snippet

Sponsor: Yu Wang | Conditions: Thyroid Cancer | Phase 2 | Status: RECRUITING